Table 2.
Baseline characteristics of the patients
| Study | Mean age (y) | Male % | Baseline NYHA class | HTN% | DM% | CAD% | MI% | Prior HF admission % |
|---|---|---|---|---|---|---|---|---|
| Noe et al. 1999 | F - 75.1 T - 75.1 |
F - 54 T - 57.3 |
F- 2.36 T- 2.34 |
F - 59.1 T - 63.1 |
F - 33.6 T - 44.7 |
NA | F - 38.0 T - 45.6 |
NA |
| Stroupe et al. 2000 | F - 63 T - 63 |
F - 35 T - 38 |
NA | F - 47 T - 53 |
F - 43 T - 40 |
NA | F - 3 T - 7 |
NA |
| Murray et al. 2001 | F - 64.1 T - 64.1 |
F - 46 T - 49 |
F - 2.6 T - 2.8 |
F - 58 T - 61 |
F - 53 T - 46 |
F - 41 T - 35 |
F - 5 T - 12 |
F - 11 T - 25 |
| Muller et al. 2003 | F - 73.2 T - 74.4 |
F - 40.9 T - 45.1 |
F - 2.37 T - 2.47 |
F - 31.3 T - 27.1 |
F - 78.3 T - 72.1 |
NA | F - 51.3 T - 41.8 |
F - 7.8 T - 13.1 |
| Yamato et al. 2003 | F - 64.9 T - 64.7 |
F - 60 T - 56 |
F - 2.6 T - 2.7 |
F - 24 T - 28 |
NA | NA | F - 48 T - 52 |
NA |
| Paterna et al. 2005 | F - 74.3 T- 73.5 |
F - 67 T - 64 |
NA | F - 21 T - 29 |
NA | F - 52 T - 50 |
NA | NA |
| TORAFIC 2011 | F - 69.3 T - 68.1 |
F - 62 T - 55 |
NYHA II F - 89.7 % T - 96.1 % | F - 100 T - 100 |
NA | NA | NA | NA |
| Trippel et al. 2018 | F - 69.3 T - 68 |
F - 39 T - 76 |
NYHA II F - 33 % T - 59 % | F - 94 T - 100 |
F - 100 T - 100 |
F - 39 T - 53 |
NA | F - 28 T - 76 |
| Balsam et al. 2019 | F - 65 T - 74 |
F - 83.3 T - 68.8 |
F - 2 T - 2 |
F - 58.3 T - 50 |
F - 50 T - 37.5 |
F - 45.8 T - 50 |
NA | F - 67.7 T - 56.3 |
| Mentz et al. 2023 | F - 65 T - 64 |
F - 61 T - 65.2 |
NA | NA | F - 47.3 T - 48.1 |
F - 26.7 T - 29.8 |
NA | F - 33.7 T - 37 |
CAD = coronary artery disease; DM = diabetes mellitus; F = furosemide; HF = heart failure; HTN = hypertension; MI = myocardial infarction; NA = not available; NYHA = New York Heart Association; T = torsemide; TORAFIC = torasemide prolonged release versus furosemide in patients with chronic heart failure; y = years.